Grants paid by Paris Brain Institute America Inc C/O Martine Assouline
EIN 92-2977507 · New York, NY · Form 990, Schedule I · NTEE H12
Paris Brain Institute America Inc C/O Martine Assouline of New York, NY (EIN 92-2977507) reported 3 grants paid totaling $266,874 to 3 recipients in tax years 2024, on Form 990, Schedule I. Derived from IRS e-file data, dataset version 2026.09.0, built 2026-09-03.
Grants paid
$266,874
3 grants
Recipients
3
distinct organizations
Tax years
2024
1 filing in the corpus
By tax year
| Tax year | Grants paid | Amount paid | Approved for future |
|---|---|---|---|
| 2024 | 3 | $266,874 | — |
Top recipients
The 3 recipients receiving the most from Paris Brain Institute America Inc C/O Martine Assouline, by grants paid, out of 3 distinct recipients.
| Recipient | Match | Location | Grants | Total paid | Latest year |
|---|---|---|---|---|---|
| Harvard University 04-2103580 | A | Boston, MA | 1 | $105,000 | 2024 |
| Columbia University 13-5598093 | A | New York, NY | 1 | $97,000 | 2024 |
| Dana-Farber Cancer Institute 04-2263040 | A | Boston, MA | 1 | $64,874 | 2024 |
Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.
Every grant
All 3 grant rows this organization reported, most recent first.
| Tax year | Recipient | Match | Amount | Type | Purpose | Source filing |
|---|---|---|---|---|---|---|
| 2024 | Harvard University Boston, MA | A | $105,000 | paid | HARVARD MEDICAL SCHOOL: FOR THE BENEFIT OF DR. SANDRO SANTAGAT'S PROJECT, ENTITLED, "UNDERSTANDING AND OVERCOMING GLIOBLASTOMA THERAPEUTIC RESISTENCE" | 202503219349325170 |
| 2024 | Columbia University New York, NY | A | $97,000 | paid | VAGELOS COLLEGE OF PHYSICIANS AND SURGEONS, DEPARTMENT OF NEUROLOGY | 202503219349325170 |
| 2024 | Dana-Farber Cancer Institute Boston, MA | A | $64,874 | paid | PARTICIPATION IN THE PERFORMANCE OF THE RESEARCH PROJECT WITH THE AIM OF DEVELOPING NEW THERAPEUTIC STRATEGIES TO TACKLE GLIOBLASTOMAS, SPECIFICALLY TO IDENTIFY VULNARABILITIES IN THERAPY RESISTANCE AND DEVELOPING NEW TARGETED STRATEGIES FOR GLIOBLASTOMA | 202503219349325170 |
Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.
Recipient matching for this dataset version has not yet completed its independent precision check. Tier A rows carry the EIN the filer reported; tiers B–D are the matcher's inference and should be read as leads until the check is published on the methodology page.
Source filings
Every figure above is traceable to one of these IRS e-file returns by its OBJECT_ID.
| Form | Tax year | Period end | Filed | Schema | IRS OBJECT_ID |
|---|---|---|---|---|---|
| 990 | 2024 | 2024-12-31 | not stated | 2024v5.2 | 202503219349325170 |
Derived from IRS Form 990 e-file XML; recipient identities from the IRS Exempt Organizations Business Master File. Dataset version 2026.09.0, built 2026-09-03. The same rows as Parquet: manifest; as JSON: /api/funders/922977507.json.
The same organization elsewhere in the program: exempt status and filing health · federal awards · grant guidance · open opportunities.
This is informational only, derived from public data on the dates shown. It is not an eligibility determination, and not legal, tax, or accounting advice. Verify against the official source before relying on it.